Trientine Tetrahydrochloride: uses, dosing, side effects & brands
Trientine Tetrahydrochloride is a medicine sold in the U.S. under one brand, for hepatolenticular degeneration and nervous system heavy metal poisoning. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Hepatolenticular Degeneration and Nervous System Heavy Metal Poisoning
- Available as
- Tablet
- Sold as
- Cuvrior
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How trientine tetrahydrochloride is dosed
From the FDA label for Cuvrior (application NDA215760). Other trientine tetrahydrochloride products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Recommended Dosage and Administration Starting total daily dosage of CUVRIOR in adults is 300 mg up to 3,000 mg orally in divided doses (2 times daily). See full prescribing information for recommended conversion table when switching from penicillamine to CUVRIOR. ( 2.1 ) Total daily dosage of CUVRIOR should not exceed 3,000 mg. ( 2.1 ) If the number of CUVRIOR tablets prescribed per day cannot be equally divided among doses, then divide total daily dosage such that the higher number of tablets is taken with the first daily dose. ( 2.1 ) Take CUVRIOR on an empty stomach. ( 2.2 ) Swallow tablets without crushing, chewing, or dissolving tablets. ( 2.2 ) Switching from Other Trientine Products CUVRIOR is not substitutable on a milligram-per-milligram basis with other trientine products. ( 2.3 ) See full prescribing information for additional information on switching from other trientine products. ( 2.3 ) Clinical Monitoring and Laboratory Monitoring of Copper Adjust CUVRIOR dosage according to clinical assessment and laboratory monitoring of copper. ( 2.4 ) See full prescribing information for monitoring recommendations. ( 2.4 ) 2.1 Recommended Dosage and Administration The recommended starting total daily dosage of CUVRIOR in adult patients is 300 mg up to 3,000 mg taken orally in divided doses (two times daily). Table 1 provides the recommended starting total daily dosage of…
Trientine Tetrahydrochloride side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Potential for Worsening of Clinical Symptoms at Initiation of Therapy [see Warnings and Precautions (5.1) ] Copper Deficiency [see Warnings and Precautions (5.2) ] Iron Deficiency [see Warnings and Precautions (5.3) ] Hypersensitivity Reactions [see Warnings and Precautions (5.4) ] Most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Common Adverse Reactions Table 3 presents common adverse reactions over a 24-week period from Trial 1, a prospective, randomized, multi-center study that was conducted in adult patients with Wilson's disease who were de-coppered and tolerant to penicillamine [see Clinical Studies (14) ] . Patients were either switched to receive CUVRIOR (N=26) or continued to receive penicillamine (N=27). Table 3: Common Adverse Reactions Adverse reactions that occurred in >5% of…
Who shouldn’t take trientine tetrahydrochloride
CUVRIOR is contraindicated in patients with hypersensitivity to trientine or to any of the excipients in CUVRIOR [see Warnings and Precautions (5.4) ] . Hypersensitivity to trientine or to any of the excipients in CUVRIOR. ( 4 )
Trientine Tetrahydrochloride drug interactions
Mineral Supplements (e.g. iron, zinc, calcium, magnesium): Avoid concomitant use. If concomitant use is unavoidable ( 2.2 , 7.1 ): Iron : Take CUVRIOR at least 2 hours before or 2 hours after iron. Other Mineral Supplements : Take CUVRIOR at least 1 hour before or 2 hours after other mineral supplements. Other Drugs for Oral Administration : Take CUVRIOR at least 1 hour apart from any other oral drug. ( 2.2 , 7.1 ) 7.1 Mineral Supplements and Other Oral Drugs CUVRIOR has the potential to chelate non-copper cations in mineral supplements and other oral drugs, and could be rendered ineffective prior to systemic absorption. Mineral Supplements Avoid concomitant use of mineral supplements such as iron, zinc, calcium, or magnesium with CUVRIOR because they may reduce the absorption of CUVRIOR. However, if iron deficiency develops [see Warnings and Precautions (5.3) ], iron supplementation may be given in short courses, but because iron and CUVRIOR each inhibit absorption of the other, administer CUVRIOR at least 2 hours before or 2 hours after administration of an iron supplement [see Dosage and Administration (2.2) ]. If concomitant use of other mineral supplements is unavoidable, administer CUVRIOR at least 1 hour before or 2 hours after administration of other mineral supplements. Other Drugs for Oral Administration Administer CUVRIOR at least 1 hour apart from any other oral drug.
Every trientine tetrahydrochloride product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Cuvrior.
What trientine tetrahydrochloride pills look like
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| OL75;OL75 | 300 mg | yellow | oval | — |
Can you crush or split trientine tetrahydrochloride?
The trientine tetrahydrochloride labels that address it permit crushing or splitting in the terms they state — quoted per product, because the instruction belongs to the form.
What each trientine tetrahydrochloride label says about crushing, splitting and chewingWhat people report to the FDA about trientine tetrahydrochloride
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 51 reports naming trientine tetrahydrochloride, and the FDA flagged 98% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- abortion spontaneous5 reports
- maternal exposure during pregnancy5 reports
- hepatic failure4 reports
- colitis3 reports
- dysphagia3 reports
- hepatic cirrhosis3 reports
- nausea3 reports
- blood copper increased2 reports
Read these as a signal, not a rate. A report does not mean trientine tetrahydrochloride caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 26, 2026.
Related calculators
Frequently asked questions
What is trientine tetrahydrochloride?
Cuvrior (Trientine Tetrahydrochloride) is a medication used to treat Hepatolenticular Degeneration, Nervous System Heavy Metal Poisoning.
Can you take trientine tetrahydrochloride with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run trientine tetrahydrochloride against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does trientine tetrahydrochloride come in?
Across the brands we track, trientine tetrahydrochloride is currently marketed as tablet, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic trientine tetrahydrochloride?
We do not currently list a generic-labelled trientine tetrahydrochloride product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Trientine Tetrahydrochloride: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/trientine-tetrahydrochloride
- MLA
- “Trientine Tetrahydrochloride: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/trientine-tetrahydrochloride.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for trientine tetrahydrochloride on DailyMed (NIH) ↗.